Treatment of immunoglobulin light chain (primary or AL) amyloidosis

By Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman

Research output: Contribution to journalReview articlepeer-review


Not all forms of amyloidosis are systemic. Some patients may present with a localized form and should not be treated with chemotherapy. Some patients with systemic amyloidosis may have secondary, familial, or dialysis-related types. These types are not responsive to chemotherapy. Immunoglobulin light chain (primary or AL) amyloidosis is a plasma cell dyscrasia. Suppression of light chain production translates to organ response, improved organ function, and improved quality of life. This review of the various available options for the treatment of systemic amyloidosis is designed to help the clinician determine which patients are candidates for stem cell transplantation and which should be treated with conventional chemotherapy. The role of the recently introduced novel agents in management of amyloidosis is also reviewed.

Original languageEnglish (US)
Issue number7
StatePublished - 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of immunoglobulin light chain (primary or AL) amyloidosis'. Together they form a unique fingerprint.

Cite this